288 related articles for article (PubMed ID: 8336188)
1. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
2. A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients.
Sosman JA; Kefer C; Fisher RI; Jacobs CD; Pumfery P; Ellis TM
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):171-80. PubMed ID: 7613643
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer.
Buter J; Janssen RA; Martens A; Sleijfer DT; de Leij L; Mulder NH
Eur J Cancer; 1993; 29A(15):2108-13. PubMed ID: 8297649
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
6. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.
Triozzi PL; Kim JA; Martin EW; Young DC; Benzies T; Villasmil PM
J Clin Oncol; 1995 Feb; 13(2):482-9. PubMed ID: 7844609
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.
Borrione P; Montacchini L; Beggiato E; Pileri A; Bianchi A; Massaia M
Leuk Lymphoma; 1996 Apr; 21(3-4):325-30. PubMed ID: 8726415
[TBL] [Abstract][Full Text] [Related]
10. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
12. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.
Kroesen BJ; Janssen RA; Buter J; Nieken J; Sleijfer DT; Mulder NH; De Leij L
J Hematother; 1995 Oct; 4(5):409-14. PubMed ID: 8581377
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.
Sparano JA; Fisher RI; Sunderland M; Margolin K; Ernest ML; Sznol M; Atkins MB; Dutcher JP; Micetich KC; Weiss GR
J Clin Oncol; 1993 Oct; 11(10):1969-77. PubMed ID: 8410122
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.
Atkins MB; Redman B; Mier J; Gollob J; Weber J; Sosman J; MacPherson BL; Plasse T
Clin Cancer Res; 2001 Mar; 7(3):486-92. PubMed ID: 11297238
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
Atkins MB; Sparano J; Fisher RI; Weiss GR; Margolin KA; Fink KI; Rubinstein L; Louie A; Mier JW; Gucalp R
J Clin Oncol; 1993 Apr; 11(4):661-70. PubMed ID: 8478661
[TBL] [Abstract][Full Text] [Related]
17. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
18. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
Lindsey KR; Rosenberg SA; Sherry RM
J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
[TBL] [Abstract][Full Text] [Related]
19. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
[TBL] [Abstract][Full Text] [Related]
20. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
